XB-IMG-130845
Xenbase Image ID: 130845
|
Fig. 5. Xpygo-2 NHD acts as a Wnt pathway activator to induce dorsal axial structures and suppress anterior neurectoderm. Embryos were either injected
in ventral vegetal blastomeres (VV) or dorsal animal blastomeres (DA) with 10 ng of Xpygo-2 PHD RNA (control) (A, C–F), Xpygo-2 / NHD RNA (B,
G–J), dominant Wnt activator R85 (K–N), or GSK-3 (O–R). Unlike PHD, overexpression of the NHD generated partial secondary axes when injected
ventrally (B). Dorsal animal injected embryos were processed at stage 35 by using pan-neural (2G9; C, G, K, O, lateral view; D, H, L, P, dorsal view), skeletal
muscle (12/101; top, lateral view; bottom, dorsal view), and Engrailed-2 (4D9, dorsal view) antibodies. 2G9 stained the anterior forebrain (f), the boundary
between forebrain and midbrain (m), hindbrain (h), and spinal cord. The eye (e) was not stained at this stage. The NHD (G, H) and R85 (K, L), unlike GSK
(O, P), disrupted anterior most staining of the forebrain (arrows). GSK disrupted or depleted midbrain staining (P, arrow). 12/101 staining indicated that all
embryos developed normal somitic muscle (E, I, M, Q). 4D9 staining showed normal or expanded Engrailed-2 localization in embryos injected with NHD
(J) and R85 (N) as compared with PHD (F) controls. GSK injection, however, reduced expression of En-2 (R, arrow). Scale bars: 1 mm (C–E); 0.1 mm (F). Image published in: Lake BB and Kao KR (2003) Copyright © 2003. Image reproduced with permission of the Publisher, Elsevier B. V. Larger Image Printer Friendly View |